Ecolab Inc. (ECL) Earnings
Ecolab Inc. is expected to report next earnings on October 27, 2026 (in NaN days), with a consensus EPS estimate of $2.18. ECL has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise -0.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 28, 2026 | $2.08 | $2.09 | +0.5% | $4.4B | +0.7% |
| Apr 28, 2026 | $1.70 | $1.70 | +0.0% | $4.1B | +1.0% |
| Oct 28, 2025 | $2.07 | $2.07 | +0.0% | $4.2B | +1.1% |
| Jul 29, 2025 | $1.90 | $1.89 | -0.5% | $4.0B | +0.1% |
| Feb 11, 2025 | $1.81 | $1.81 | +0.0% | $4.0B | +0.5% |
| Jul 30, 2024 | $1.67 | $1.68 | +0.6% | $4.0B | -1.2% |
| Feb 13, 2024 | $1.54 | $1.55 | +0.6% | $3.9B | +0.1% |
| Oct 31, 2023 | $1.52 | $1.54 | +1.3% | $4.0B | -1.2% |
| May 2, 2023 | $0.86 | $0.88 | +2.3% | $3.6B | +2.8% |
| Feb 14, 2023 | $1.25 | $1.27 | +1.6% | $3.7B | -0.9% |
| Nov 1, 2022 | $1.31 | $1.30 | -0.8% | $3.7B | +0.3% |
| Jul 26, 2022 | $1.09 | $1.10 | +0.9% | $3.6B | +2.7% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 28, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Overall Quarterly Performance - Delivered strong accelerating Q2 performance with 5% organic sales growth and 11% adjusted EPS growth, meeting management expectations for the transition quarter of energy surcharge implementation. - Pricing strengthened to 4% in Q2, after rapid implementation of a global energy surcharge to offset rising commodity costs, with stable organic gross margin maintained despite cost increases. - Excluding the ~1% headwind from Middle East customer operational disruptions, underlying volume growth accelerated from the first quarter, with overall reported volume growth of 1%. Growth Engine Progress - Life Sciences: Has scaled from under $100 million in 2017 to nearly $1 billion today, driven by strong share gains in bioprocessing, pharma, personal care, and purification, after years of targeted investment. Capacity expansions across North America, Europe, and Asia have unlocked additional growth. - Ecolab Digital: Grew 27% driven by strong adoption of new connected software solutions including DishIQ, AquaIQ, KitchenIQ, and CIPIQ. The business has 800,000 connected customer devices on track to hit 1 million by year-end, with a long-term target of 20%+ annual growth and $3 billion in potential revenue from existing customers. - Pest Elimination: Delivered 7% growth driven by share gains from the One Ecolab initiative, with ongoing investment in digital pest intelligence technology to deliver near 99% pest-free customer environments. - Global High-Tech: Grew 29% driven by strong demand from AI infrastructure buildout for microelectronics and data centers. The July 2024 acquisition of CoolIT Systems (which had 100%+ year-to-date growth pre-acquisition) strengthens the company's end-to-end solution for data center cooling. Strategic Portfolio Shifts - The company's portfolio is actively shifting toward higher-growth, higher-margin end markets, with growth engines expected to reach ~25% of total company sales by 2027. - The One Ecolab integrated operating model is driving cross-selling and growth in core segments, particularly food and beverage where integrated water and food safety teams have outperformed the broader flat industry. - A new breakthrough integrated end-to-end data center cooling platform combining CoolIT liquid cooling and Ecolab 3D TRASAR digital technology will be launched at the Supercomputing conference in November 2026, and an Investor Day will be held there to share updated long-term growth plans.
Guidance
- Full year 2026 adjusted EPS guidance is raised to $8.05 to $8.25, representing 7% to 10% growth year-over-year, with the range reflecting short-term noncash amortization and financing costs from the CoolIT acquisition. - Pricing is expected to reach 5% to 6% in the second half of 2026 as energy surcharge benefits are fully realized, enabling offset of rising commodity costs. - Organic sales growth is expected to be 6% to 7% in the second half of 2026, driving an adjusted operating income margin of 19% for H2 2026, keeping the company on track to hit its 20% operating income margin target for 2027. - Global High-Tech is expected to grow more than 25% annually, reaching $4 billion in sales by 2030 with a 25% operating income margin. This is an upward revision from prior targets of 20% annual growth and 20% operating income margin. - Long-term, the company reaffirms its targets of 5% to 7% annual organic sales growth, 12% to 15% annual adjusted EPS growth, and operating income margins expanding beyond 20% after 2027. The 2027 20% operating income margin target remains unchanged despite the CoolIT acquisition.
Segment performance
Overall, the company delivered 5% accelerating organic sales growth and 11% adjusted EPS growth in Q2 2026. By segment/growth grouping: 1. Core businesses (including Food & Beverage, Institutional & Specialty): Food & Beverage grew 7% organic, Institutional & Specialty grew 4% organic. Core businesses now represent ~70% of sales, growing mid-single digits with operating income (OI) margin above 20%. 2. Growth engines: Life Sciences accelerated to 15% organic growth, delivered a mid-20% OI margin in Q2; Ecolab Digital grew 27% organic; Pest Elimination grew 7% organic; Global High-Tech accelerated to 29% organic growth. Growth engines represent ~15% of 2026 sales, growing low-double digits with OI margin near 20%. Pro forma including acquired CoolIT and Ovivo, overall company sales growth would have been ~7% in Q2. 3. Underperforming businesses (including Heavy Water, Paper): Performance improved in Q2, after over a year of negative sales declines, the segment has stabilized, maintains mid-teens OI margins, and is seeing early positive growth momentum. Global High-Tech is now the company's largest growth engine, with $1.5 billion in annualized sales (up from $150 million in 2021) after the CoolIT acquisition.
Risks & headwinds
- Ongoing operational disruption from the Middle East conflict creates a sustained ~1% headwind to overall company volume growth, with no near-term expectation of resolution. - Rapid demand growth in high-growth segments including Life Sciences and Global High-Tech requires continued investment ahead of growth, which suppresses near-term reported margins even as long-term return profiles remain strong. - Commodity and energy price volatility creates ongoing pressure on gross margins, requiring timely pricing adjustments that depend on customer acceptance. - Macroeconomic weakness impacting consumer food traffic (down 5% year-over-year in U.S. restaurants) creates headwinds for the Institutional & Specialty segment, though the business is outperforming the broader industry.
Analyst Q&A
Q: How does Ecolab reaffirm its 2027 20% operating income margin target after the CoolIT acquisition, which adds incremental amortization expense? /
A: Management confirms the 2027 20% OI target remains unchanged. The vast majority of Ecolab's businesses are already at or above 20% margin, and H2 2026 is on track to hit 19% adjusted OI margin, trending toward the 2027 target. Incremental amortization from CoolIT will be offset by the expiration of Nalco acquisition amortization next year, keeping the target on track. The second half of 2027 will see even stronger margin performance after the first 12 months of CoolIT amortization is annualized. (317 characters)
Q: What is the current business split for global high-tech, and how confident are you in the $4 billion 2030 sales target? /
A: Global high-tech is currently $1.5 billion annualized, split roughly evenly into three $500 million segments: legacy microelectronics/data center business, acquired Ovivo (microelectronics focused), and acquired CoolIT (data center cooling). All three segments are growing strongly: legacy grew 29% in Q2, Ovivo is expected to deliver mid-teens growth this year, and CoolIT is growing over 100% year-to-date. Management views the 25% annual growth trajectory to $4 billion by 2030 as realistic and feels confident in the target. (348 characters)
Q: How much of Life Sciences 15% Q2 growth comes from end market growth, share gains, and capacity unlock, after years of underperformance? /
A: Life Sciences growth reflects a combination of all three factors. After the 2021 Purolite acquisition, the business faced COVID-related market disruptions and grew slower than planned but still outperformed competitors. The team used that period to build out required capacity, capabilities, and customer relationships across global regions. Today, the business is back on track to meet its original return targets, driven by consistent share gains across the entire drug development pipeline from early stage to commercial production, with newly opened capacity in China removing prior constraints. (362 characters)
Q: What is driving food and beverage's 7% Q2 growth, which outperforms the broader flat industry, and can this acceleration continue? /
A: The primary driver is the One Ecolab integrated operating model, which combined previously separate food safety and water teams into a single integrated customer-facing organization, starting with North America. This structure drives meaningful cross-selling: selling food safety solutions to existing water customers and water solutions to existing food safety customers, while delivering more value to customers by aligning capabilities around their core needs. Food safety is also increasingly top of mind for producers and end customers, increasing demand for Ecolab's solutions. The integrated model is now being rolled out globally, providing sustained growth momentum for coming quarters. (396 characters)
Q: Why doesn't margin expand more materially in H2 2026 despite the expected 5% to 6% pricing, and what commodity inflation assumptions are you using? /
A: Guidance uses the most up-to-date commodity price information, and currently assumes high-single-digit commodity price inflation for the balance of 2026. Gross margin math means pricing must be roughly double cost increases to maintain margin, and the business achieved this stabilization in just three months, a marked improvement from the two-year cycle common in prior inflationary periods. There is also a ~60 basis point gross margin drag from the recently acquired Ovivo business that impacts reported H2 margins. Once commodity costs stabilize, the pricing put in place will flow through to incremental margin, as Ecolab does not reverse pricing after cost increases pass. (387 characters)